US FDA approves Axsome's drug for Alzheimer's-related agitation - Reuters
US FDA approves Axsome's drug for Alzheimer's-related agitation Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWVphYlZWc0RER3F3c09sMXhsQkE4b0lzaXhWM3FYV2lza19mU3Y1WWI4WElZbmxOc3FGUE9UaUN2VmVQYjRuaHJQU0lQS3V5Y2Z5Wk1lVkNGelEyMHMwSXR1YWRWYk9ULV9zTFBvX291RmpHakpodm04MHpfWl9lZlVhVGdiM2tiQ3BWb080NWFrR1VUdUxsb2FmTE5LT2xnSlZrVHotRzY3OHV0d0d2djlUSUVEV3lQeXY5VnBvWWlHUTZZNXd1Yw?oc=5" target="_blank">US FDA approves Axsome's drug for Alzheimer's-related agitation</a> <font color="#6f6f6f">Reuters</font>
The FDA approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) for treating agitation in Alzheimer's patients, marking the first non-antipsychotic treatment for this condition.
Axsome Therapeutics announced the FDA approval of Auvelity for treating agitation associated with Alzheimer's disease, a first-in-class treatment targeting NMDA and sigma-1 receptors.
The FDA approved Axsome Therapeutics' drug, Auvelity, to treat agitation in Alzheimer's patients, offering an alternative to antipsychotic drugs.
Axsome Therapeutics received FDA approval for Auvelity to treat Alzheimer's disease agitation, accessing a $1 billion-plus market and offering a clean label compared to competitors.
The FDA approved Axsome Therapeutics' Auvelity for treating agitation in Alzheimer's disease, providing a new option to ease caregiver burden.
Similar Stories
Related coverage based on topic and tags
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance - Reuters
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance Reuters
August 24, 2026 at 05:39 PMUS FDA expands approval for J&J's drug for rare blood disorder - Reuters
US FDA expands approval for J&J's drug for rare blood disorder Reuters
August 24, 2026 at 10:49 PMAstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial - Reuters
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial Reuters
August 27, 2026 at 06:10 AMUS FDA approves Roivant-Priovant's skin and muscle disease drug - Reuters
US FDA approves Roivant-Priovant's skin and muscle disease drug Reuters
August 27, 2026 at 10:42 PMRevolution's lifesaving pancreatic cancer drug wins speedy FDA approval - Reuters
Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval Reuters
August 26, 2026 at 06:18 PMChina approves J&J psoriasis pill Icotyde, says drugmaker - Reuters
China approves J&J psoriasis pill Icotyde, says drugmaker Reuters
August 27, 2026 at 05:02 PM